In last trading session, Standard BioTools Inc (NASDAQ:LAB) saw 1.21 million shares changing hands with its beta currently measuring 1.31. Company’s recent per share price level of $1.25 trading at $0.01 or 0.81% at ring of the bell on the day assigns it a market valuation of $474.78M. That closing price of LAB’s stock is at a discount of -92.8% from its 52-week high price of $2.41 and is indicating a premium of 26.4% from its 52-week low price of $0.92. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.72 million shares which gives us an average trading volume of 1.80 million if we extend that period to 3-months.
For Standard BioTools Inc (LAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.04 in the current quarter.
Standard BioTools Inc (NASDAQ:LAB) trade information
Standard BioTools Inc’s shares saw a change of -40.76% in year-to-date performance and have moved -7.41% in past 5-day. Standard BioTools Inc (NASDAQ:LAB) showed a performance of 13.64% in past 30-days. Number of shares sold short was 16.16 million shares which calculate 11.03 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3.25 to the stock, which implies a rise of 61.54% to its current value. Analysts have been projecting 3.25 as a low price target for the stock while placing it at a high target of 3.25. It follows that stock’s current price would drop -160.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -160.0% for stock’s current value.
Standard BioTools Inc (LAB) estimates and forecasts
This year revenue growth is estimated to fall -3.04% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 39.83M for the same. And 3 analysts are in estimates of company making revenue of 40.87M in the next quarter. Company posted 37.2M and 44.97M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.61% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 55.47% while estimates for its earnings growth in next 5 years are of 66.44%.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Insiders are in possession of 1.53% of company’s total shares while institution are holding 73.09 percent of that, with stock having share float percentage of 74.22%. Investors also watch the number of corporate investors in a company very closely, which is 73.09% institutions for Standard BioTools Inc that are currently holding shares of the company. CASDIN CAPITAL, LLC is the top institutional holder at LAB for having 63.96 million shares of worth $113.21 million. And as of 2024-06-30, it was holding 17.1782 of the company’s outstanding shares.
The second largest institutional holder is VIKING GLOBAL INVESTORS LP, which was holding about 58.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.7524 of outstanding shares, having a total worth of $103.81 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 9.17 shares of worth $11.46 million or 2.41% of the total outstanding shares. The later fund manager was in possession of 7.29 shares on May 31, 2025 , making its stake of worth around $9.11 million in the company or a holder of 1.92% of company’s stock.